What Antibiotic Susceptible and Resistant Mean: MIC Explained

An antimicrobial susceptibility report links a microorganism, a drug, a laboratory measurement, and an interpretation. The minimal inhibitory concentration, or MIC, is the lowest concentration tested that prevents visible growth under defined conditions. The laboratory then compares that MIC with a breakpoint for the specific organism-drug pair.

“Susceptible” means the isolate is likely to respond when the drug is used under the regimen and infection-site assumptions behind that breakpoint. “Resistant” means usually achievable drug levels are unlikely to inhibit the isolate reliably or a resistance mechanism makes clinical success doubtful. Neither word is a guarantee about one patient, and the MIC is not a treatment dose.

How an MIC is measured#

Reference broth microdilution places a standardized amount of the organism into wells containing serial twofold concentrations of an antimicrobial. A panel might move from 0.25 to 0.5 to 1 to 2 micrograms per milliliter. After controlled incubation, the MIC is the lowest tested concentration without visible growth.

Broth macrodilution uses larger tubes. Agar dilution incorporates different drug concentrations into agar. Gradient diffusion places a strip with a concentration gradient on an inoculated plate, and the MIC is read where the inhibition ellipse meets the scale. Automated systems use proprietary cards or panels and algorithms validated against reference methods. Disk diffusion measures the diameter of a growth-free zone rather than an MIC, then applies zone-diameter breakpoints.

The method is standardized because inoculum density, medium composition, pH, incubation temperature, atmosphere, duration, and endpoint reading can move a result. Fastidious organisms need modified media or conditions. Some drug-organism combinations require special methods because routine methods perform poorly.

MIC panels test a finite range. A report of <=0.25 tells you there was no growth at the lowest concentration on that panel; the true MIC could be lower. >16 means growth persisted at the highest tested concentration; it does not identify the exact higher value.

Why twofold dilutions matter#

MIC is not infinitely precise. Repeating a standardized test commonly produces a result within one twofold dilution of the first result. A measured 1 on one run and 2 on another may reflect ordinary method variation rather than biological change.

That matters near a breakpoint. If the susceptible cutoff is 1, a shift from 1 to 2 can change the printed category. Standards include quality-control strains and ranges to detect a method that has drifted, but they cannot remove all biological and technical variation. That is why a category is often more clinically interpretable than false decimal precision, though the actual MIC can still earn its place in resistance detection, referral testing, pharmacokinetic-pharmacodynamic analysis, or a difficult infection, provided you respect its uncertainty.

A breakpoint is more than a laboratory cutoff#

Clinical breakpoints integrate several evidence streams. MIC distributions show how a species behaves and where acquired resistance may create a separate population; drug studies show the relationship among dose, blood and tissue concentrations, time, and bacterial killing; clinical outcomes show which regimens succeed in defined infections; and mechanistic data identify enzymes, altered targets, pumps, or permeability changes.

FDA recognizes susceptibility test interpretive criteria in the United States and posts updates online. CLSI publishes widely used methods and breakpoint tables. EUCAST publishes another major system. Their categories and assumptions can differ, so the standard your laboratory names matters.

Breakpoints are specific to an organism and drug, and sometimes to a route, regimen, or site. The same numerical MIC can be susceptible for one drug and resistant for another. A breakpoint for urinary infection may not answer meningitis. A breakpoint for one bacterial species should not be borrowed for another unless the standard says to do so.

What susceptible actually predicts#

FDA defines susceptible around inhibition by usually achievable concentrations with the recommended regimen for the infection site, implying likely clinical efficacy. It is a probability statement under assumptions.

Success can still fail if the cultured organism is not the true cause, an abscess or infected device needs source control, the drug does not reach the site, absorption is poor, the immune system is severely impaired, therapy starts late, or the prescribed course is not taken. A susceptible urinary isolate does not prove that the same drug is suitable for bloodstream or central nervous system infection.

Conversely, clinical improvement does not prove the report was wrong if an isolate is labeled resistant. The illness may have been nonbacterial, source control may have cured it, another drug may have been active, or drug levels at a particular site may have been unusually high. Categories estimate outcomes across populations rather than certify causation in one episode.

What resistant means#

Resistant indicates that the isolate is not inhibited by concentrations usually achieved with recommended regimens, that a clinically important resistance mechanism is likely, or that efficacy has not been reliable in studies. It is a strong warning against relying on that organism-drug combination.

Resistance may arise through drug-destroying enzymes such as beta-lactamases, target alteration, reduced entry, efflux pumps, bypass pathways, or combinations. A phenotype can imply broader resistance than the single tested agent. Laboratories may suppress certain results or add comments based on validated reporting rules.

“Resistant” describes the organism under the test and breakpoint. It does not mean the person's body is resistant to antibiotics. It also does not mean every drug in a class will fail unless class rules or the mechanism support that inference.

Intermediate, SDD, and different standards#

The CLSI intermediate category can act as a buffer around a breakpoint, acknowledge lower response rates, or indicate possible efficacy at sites where a drug concentrates. Susceptible dose-dependent, abbreviated SDD, means the probability of success depends on a regimen that achieves higher or more sustained drug levels than the regimen underlying the susceptible category.

EUCAST uses S, I, and R but assigns a different operational meaning to I: likely success when drug levels are increased through an adjusted regimen or high concentration at the site. Do not assume that an I from one standards system means what an I from another means; check which system produced the report.

These labels are not permission to improvise a dose. Product labeling, organ function, toxicity, drug interactions, site, and specialty guidance constrain the regimen. The laboratory can identify the category; the clinical team must decide whether a supported regimen is feasible and safe.

MIC, ECOFF, and resistance genes answer different questions#

An epidemiological cutoff, often called an ECOFF or ECV, separates a species' wild-type MIC distribution from isolates likely to carry an acquired or mutational resistance mechanism. It is a microbiological boundary, not necessarily a clinical success boundary.

A molecular test detects selected resistance genes or mutations. That can provide a rapid answer before culture is complete, but genes do not cover every mechanism. A detected gene may predict resistance even when an early phenotype seems low. A negative gene panel does not prove susceptibility if the panel omits the relevant mechanism. Phenotypic testing asks whether growth is inhibited under laboratory conditions, genotypic testing asks whether defined resistance determinants are present, and identification methods ask which organism is present. These are complementary rather than interchangeable.

The specimen comes before the susceptibility table#

An elegant antibiogram is useful only if the isolate is clinically meaningful. Skin flora in one blood-culture bottle may represent contamination, or it may be a true device infection. Bacteria in urine can represent asymptomatic bacteriuria rather than a symptomatic infection. Respiratory samples can include colonizing organisms.

Specimen quality, collection before antibiotics, number of positive cultures, quantity, symptoms, inflammatory response, imaging, host factors, and the presence of hardware all affect interpretation. Treating colonization can cause adverse effects and select resistance without helping the patient.

Polymicrobial infections add complexity. A report may list several organisms, but not every recovered organism needs equal targeting. Source control and syndrome-specific evidence can matter more than choosing the broadest drug with an S beside it.

Why the lowest MIC is not a ranking system#

Suppose drug A has an MIC of 0.5 and a susceptible breakpoint of 1, while drug B has an MIC of 4 and a susceptible breakpoint of 8. Both are one twofold dilution below their cutoff. The raw numbers use different pharmacologic scales; 0.5 is not proof that A is more potent in the patient.

Choice also considers clinical-trial evidence for the syndrome, route, tissue penetration, toxicity, allergy history, interactions, kidney and liver function, ecological effect, spectrum, convenience, and local resistance. A narrower active drug may be preferable to a broader one, but that is a clinical judgment, not a rule contained in the MIC. The ratio between a breakpoint and an MIC can be tempting as a score, and it is not universally validated for ranking routine options, because breakpoints encode different regimens and evidence and a measured MIC has interval uncertainty.

Breakpoints can change#

As resistance evolves and pharmacologic or outcomes data improve, standards bodies revise breakpoints. A historical isolate can therefore receive a different category under a current table even though its stored MIC has not changed.

Automated instruments and their cleared software may lag behind a newly recognized breakpoint. Laboratories use verification, supplemental testing, comments, or manual interpretation under regulatory and accreditation rules. FDA's 2023 guidance addresses how device manufacturers update breakpoint labeling.

When two reports conflict, ask about the organism identification, specimen, MIC or zone, method, standards body and edition, device software, special confirmatory tests, and whether the same isolate was tested. Take the newer-looking category without that context and it can mislead you.

When a result may need another look#

Unexpected resistance, an unusual organism, a critical infection, or a result known to be difficult on automated systems may prompt reference testing. Laboratories may confirm carbapenemase production, methicillin resistance, inducible resistance, heteroresistance, or other patterns according to validated algorithms.

Repeat culture can be informative if infection persists, recurs, or arises at a new site. Therapy can select a resistant subpopulation, and a later isolate may not be biologically identical to the first. Whole-genome or typing methods may be needed to establish relatedness in outbreaks; the same species name alone does not prove the same strain.

Sources#

1. FDA-recognized antimicrobial susceptibility test interpretive criteria
2. CLSI M100 performance standards for antimicrobial susceptibility testing
3. CLSI M07 dilution susceptibility test methods
4. EUCAST clinical breakpoint tables, version 16.1
5. EUCAST MIC determination methods and reading guide
6. CDC NARMS antimicrobial resistance glossary

Antimicrobial selection requires the full clinical and laboratory context.*